Candor on gene therapy, Abiomed is warned, & BTK success in MS
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Category: biotechnology
STAT+: Cell and gene therapy CEOs share survival strategies amid biotech slump
CARLSBAD, Calif. — Biotech CEOs leading cell and gene therapy companies spoke frankly at a…
STAT+: HHS dispatches millions to next-generation Covid targets, including intranasal vaccine
WASHINGTON — The Biden administration announced Friday that it is investing in three potential vaccines…
Vampiric cancer cells, a brain atlas, & alleged misconduct at Cassava
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Amgen reports first clinical data on new targeted cancer therapy
It’s been a busy week for a cancer drug target called PRMT5 that may play…
STAT+: European regulators once again recommend Amylyx’s ALS drug be rejected
LONDON — European regulators on Friday reiterated their view that an ALS treatment from Amylyx…
STAT+: Like a vampire, some cancer cells can suck the energy source from immune cells
As elite hunters of the immune system, T cells are constantly prowling our bodies for…
Listen: Merger Mondays, Ozempic panic, & CRISPR’d pigs
When is a billion-dollar deal a bad omen? Has Wall Street gone overboard on Ozempic?…
Cell and gene therapies could be a safer bet than other drugs
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Peter Marks on creating Operation Warp Speed, but for rare diseases
Peter Marks wants drug developers to ask more stupid questions. It’s part of the top…
STAT+: Life sciences deals on track to hit lowest point since 2017
It’s no secret that biotech industry funding has fallen from its Covid highs. But with…
STAT+: European regulators consider appeal over Amylyx ALS drug
LONDON — This week, European regulators are considering an appeal from Amylyx Pharmaceuticals after initially…
With Ozempic, Wall Street moves on from a whole other class of medicines
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: ‘Like playing the lottery’: A mixed picture for laid-off life sciences workers in Massachusetts
Gina Calvanese got laid off from Jounce Therapeutics, a struggling Cambridge biotech, in April but…
STAT+: Sana to lay off nearly a third of staff, de-prioritize a key program
Sana Biotechnology, a startup that just a couple years ago raised over $1 billion off…
To protect chickens from bird flu, researchers try to CRISPR in immunity
LONDON — In this case, it was neither the chicken nor the egg that came…
Want a biotech buyout? Target cancer
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Akero’s treatment for NASH falls short in cirrhosis study
Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for…
STAT+: Bristol ‘take-under’ of Mirati is not so great for biotech, but company’s new cancer target has potential
Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics: A take-under deal feels meh…
STAT+: FDA rejects Alnylam’s heart disease treatment over insufficient data
The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart…
STAT+: Delfi launches its blood test to screen for lung cancer – and reveals challenges for liquid biopsies
Delfi Diagnostics, a well-funded startup in the burgeoning field of creating blood tests to detect…
Inflammation gets its own research center, thanks to Chan Zuckerberg Initiative
CHICAGO — At what point does inflammation, a key component of the body’s immune defense…
NIH funds expanded access projects for ALS
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: FDA advisory panel signals lack of confidence in data on Amgen’s cancer drug
The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following…
Listen: Is the Nobel committee evolving? Plus, preventing public health’s wiliest virus
Will we ever get an HIV vaccine? And is the oft-criticized institution that awards the…
STAT+: Neurocrine reports second late-stage trial success for congenital adrenal hyperplasia drug
SAN DIEGO — Neurocrine Biosciences, a biotech focused on treating rare neurological and endocrine diseases,…
Moderna’s plan to make a single vaccine for Covid, influenza, and RSV is on track
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Kyowa Kirin to acquire Orchard Therapeutics, maker of gene therapy Libmeldy
LONDON — The Japanese firm Kyowa Kirin is acquiring gene therapy maker Orchard Therapeutics in…
STAT+: Failed biotech gives a rare peek inside the tough breaks — and tough choices — that led to its demise
SAN DIEGO — It was spring 2020, and Histogen, a small biotech with big ambitions…
The major biotech news updates you need to read today
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Gene therapy makers wonder if they can make a profit in Europe. Patients fear being left behind — again
LONDON — It was when she was 12 that doctors first raised the prospect of…
STAT+: FDA finds ‘potential systemic bias’ in Amgen’s KRAS drug trial ahead of advisory meeting
A follow-up study of a first-of-its-kind cancer treatment may reflect systemic biases, the Food and…
When is a Wall Street disappointment ‘good enough’ for the FDA?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
.jpg)
STAT+: Lilly bolts another one on, acquiring Point Therapeutics for $1.4 billion
A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it…
STAT+: Syndax’s leukemia drug succeeds in pivotal study
Syndax Pharmaceuticals’ treatment for a genetically defined form of advanced leukemia met its goal in…
STAT+: Mirum’s Chenodal succeeds in late-stage trial for rare metabolic disorder
Mirum Pharmaceuticals reported on Monday that a drug it recently acquired to treat cerebrotendinous xanthomatosis,…
STAT+: The biotech scorecard for the fourth quarter: 16 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth…
STAT+: What we owe ALS patients — and why one company fell short
What do you say to a patient when the FDA rejects “their” experimental drug —…
STAT+: Taysha Gene Therapies’ plan to tackle rare diseases is crumbling
In 2020, as biotech stocks surged amid the pandemic, a startup called Taysha Gene Therapies…
Listen: Who discovered GLP-1? Plus: BrainStorm at the FDA and biotech’s slump
When is negative data positive enough? Who gets credit for scientific breakthroughs? And wasn’t biotech…
Exodus of life scientists from academia reaches historic levels, new data show
New data released Thursday by the National Science Foundation show the exodus of young life…
STAT+: What will Novo’s VC do with its influx of cash? Don’t expect obesity investments
The Danish pharmaceutical company Novo Nordisk has shepherded all kinds of medical innovation in the…
A STAT analysis shows how top drug companies are starting to take action on climate
This article is adapted from STAT’s exclusive analysis in the STAT Report: “Climate rankings: How top…
STAT+: 6 ways the government could help address drug shortages, including in cancer
WASHINGTON — Republicans and Democrats alike want to stop drug shortages from happening. The vexing…
STAT+: FDA advisers vote overwhelmingly against ALS treatment from BrainStorm
A panel of independent advisers to the Food and Drug Administration voted overwhelmingly against a…
STAT+: U.S. government’s next-gen Covid effort gives small biotech up to $433 million
The U.S. government’s “Project Nextgen,” its effort to accelerate and streamline the rapid development of…
Gene therapy death was caused by an unknown risk of the virus used, study suggests
Last October, a 27-year-old man with Duchenne muscular dystrophy died after receiving a CRISPR-based treatment…
.jpg)
Octopus tentacles inspired a new drug delivery patch that sticks to the inside of your cheek
The story of the latest development in drug administration technology — a mouth patch that…
STAT+: ARPA-H finally settles on its headquarters: hubs in Boston, Texas, and D.C.
WASHINGTON — Cities and states have been clamoring to play host to the Advanced Research…
STAT+: Just how much money do drugmakers gain from patent extensions?
Extending patent protection doesn’t just stretch a drug’s profits — in some cases, doing so…